Connor Iapoce

Rates of visual acuity loss among patients with neovascular age-related macular degeneration did not vary significantly in pre‐versus post‐lockdown time periods.

Factors including a longer diabetes duration and lower eGFR were associated with suboptimal treatment response to aflibercept in patients with DME.

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

New phase 2 study findings link levosulpiride treatment for 8 weeks with improved visual and structural outcomes and no significant adverse side effects.

The analysis found any metformin use decreased the odds of developing dry AMD, particularly cumulative 2-year doses of 1 to 270 g and 271 to 600 g.

A posthoc analysis of the phase 3 HAWK and HARRIER trials shows brolucizumab outperforms aflibercept at reducing SHRM thickness in eyes with nAMD.

On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.

Results from a cross-sectional analysis of NHANES data found a short sleep duration was associated with an increased risk of early AMD.

New data suggest patients with nAMD on prior anti-VEGF therapy experienced improved visual acuity and macular OCT parameters after switching to faricimab.

Findings from two recent studies provide insight into the association between anti-VEGF treatment for retinal diseases and the risk of kidney injury.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

Results from a secondary analysis of PALADIN showed the 0.19-mg implant was associated with mostly stable IOPs in eyes with DME over a 36-month period.

Results from the 2-year retrospective cohort study showed patients with DME and extremely high or low eGFR had a greater decline in eGFR.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

A treat-and-extend faricimab regimen may improve functional and anatomical outcomes at 1 year in patients with DME recalcitrant to aflibercept treatment.

The study evaluated 10-year outcomes of anti-VEGF therapy using a PRN treatment regimen for eyes with neovascular AMD in real-world clinical practice.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

ORION-8 results showed the change in LDL-C from baseline in the 3-year open-label extension was similar to the change observed during 18 months of placebo-controlled comparison.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.

The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

Across 31 centers in England, hybrid closed-loop therapy was associated with improvements in HbA1c, sensor glucometrics, and diabetes-related distress in adults with T1D.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A study of more than 15,000 individuals suggests regular physical activity may help prevent the development of atrial fibrillation, as well as the incidence of stroke and MACE.

Early rapid weight gain after diagnosis of T1D may play a role in the lack of remission and shorter duration of partial remission, potentially due to altered insulin sensitivity.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.